Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2012 Oct 9;107(8):1442-3; author reply 1444.
doi: 10.1038/bjc.2012.419. Epub 2012 Sep 27.

KRAS Mutation in Colorectal Cancer Metastases After Adjuvant FOLFOX for the Primary

Free PMC article
Comment

KRAS Mutation in Colorectal Cancer Metastases After Adjuvant FOLFOX for the Primary

J-N Vauthey et al. Br J Cancer. .
Free PMC article

Comment on

Similar articles

See all similar articles

Cited by 1 article

References

    1. Andreou A, Kopetz S, Maru DM, Chen SS, Zimmitti G, Brouquet A, Shindoh J, Curley SA, Garrett C, Overman MJ, Aloia TA, Vauthey JN. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Ann Surg. 2012;256:642–650. - PMC - PubMed
    1. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA. Kirsten ras mutations in patients with colorectal cancer: the multicenter ‘RASCAL' study. J Natl Cancer Inst. 1998;90:675–684. - PubMed
    1. Etienne-Grimaldi MC, Cardot JM, Francois E, Renee N, Douillard JY, Gamelin E, Milano G. Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients. Clin Pharmacol Ther. 2008;83:413–415. - PubMed
    1. Italiano A, Hostein I, Soubeyran I, Fabas T, Benchimol D, Evrard S, Gugenheim J, Becouarn Y, Brunet R, Fonck M, Francois E, Saint-Paul MC, Pedeutour F. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol. 2010;17:1429–1434. - PubMed
    1. Kawamoto Y, Tsuchihara K, Yoshino T, Ogasawara N, Kojima M, Takahashi M, Ochiai A, Bando H, Fuse N, Tahara M, Doi T, Esumi H, Komatsu Y, Ohtsu A. KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer. Br J Cancer. 2012;107:340–344. - PMC - PubMed
Feedback